Скачать или смотреть Oxford Brain Diagnostics Ltd - Cortical Disarray Measurement

Cortical Disarray Measurement (CDM®) software as a device has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA). Only our proprietary technology analyses grey matter quality and uncovers insights of the kind that we do, based on changes in the brain at a cellular level.

Dr Steven Chance (CEO & Co-Founder) and Prof. Mark Jenkinson (Co-Founder) are world-leading authorities in neuropathology and neuroimaging. The Minicolumn anatomy which lies at the heart of the CDM® method, is altered in the neuropathology of Alzheimer’s disease, and other neurological and psychiatric disorders. Our method is built on decades of direct observation of brain tissue and MRI research at the University of Oxford.

Our platform can be applied across multiple neurological and psychiatric disorders. CDM® technology is already being explored commercially by drug developers to study neurodegeneration in Alzheimer’s, Neuroinflammation and Parkinson’s Disease.